Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors

Autor: Joris Veltman, Fridlyand J, Pejavar S, Ab, Olshen, Je, Korkola, DeVries S, Carroll P, Wl, Kuo, Pinkel D, Albertson D, Cordon-Cardo C, An, Jain, Fm, Waldman

Publikováno v: Cancer Research, 63, 11, pp. 2872-80
ResearcherID
Cancer Research, 63, 2872-80
Europe PubMed Central
Scopus-Elsevier

Item does not contain fulltext Genome-wide copy number profiles were characterized in 41 primary bladder tumors using array-based comparative genomic hybridization (array CGH). In addition to previously identified alterations in large chromosomal reg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0233ab4e583a010bb92d1acb95c7bf0b
https://hdl.handle.net/2066/124793

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.

Autor: Yu K; Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States., Basu A; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., Yau C; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., Wolf DM; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States., Goodarzi H; University of California, San Francisco, San Francisco, CA, United States., Bandyopadhyay S; University of California, San Francisco, San Francisco, CA, United States., Korkola JE; Oregon Health and Science University, Portland, OR, United States., Hirst GL; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., Asare S; Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.; QuantumLeap Healthcare Collaborative, San Francisco, CA, United States., DeMichele A; University of Pennsylvania, Philadelphia, PA, United States., Hylton N; University of California, San Francisco, San Francisco, CA, United States., Yee D; University of Minnesota, Minneapolis, MN, United States., Esserman L; Department of Surgery, University of California, San Francisco, San Francisco, CA, United States., van 't Veer L; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, United States., Sirota M; Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States.; Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Jun 13; Vol. 13, pp. 1192208. Date of Electronic Publication: 2023 Jun 13 (Print Publication: 2023).

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.

Autor: Tatarova Z; Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA., Blumberg DC; Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Portland, OR, USA., Korkola JE; Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Heiser LM; Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Muschler JL; Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Schedin PJ; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Ahn SW; Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA., Mills GB; Division of Oncologic Sciences, Oregon Health & Science University, Portland, OR, USA., Coussens LM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA., Jonas O; Department of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. ojonas@bwh.harvard.edu., Gray JW; Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Portland, OR, USA. grayjo@ohsu.edu.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. grayjo@ohsu.edu.

Publikováno v: Nature biotechnology [Nat Biotechnol] 2022 Dec; Vol. 40 (12), pp. 1823-1833. Date of Electronic Publication: 2022 Jul 04.

A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses.

Autor: Gross SM; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Dane MA; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Smith RL; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Devlin KL; Department of Biomedical Engineering, OHSU, Portland, OR, USA., McLean IC; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Derrick DS; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Mills CE; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., Subramanian K; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., London AB; Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Torre D; Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Evangelista JE; Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Clarke DJB; Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Xie Z; Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Erdem C; Department of Chemical and Biomolecular Engineering, Clemson University, Clemson, SC, USA., Lyons N; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Natoli T; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Pessa S; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lu X; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Mullahoo J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Li J; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Adam M; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Wassie B; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Liu M; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Kilburn DF; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Liby TA; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Bucher E; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Sanchez-Aguila C; Department of Biomedical Engineering, OHSU, Portland, OR, USA., Daily K; Sage Bionetworks, Seattle, WA, USA., Omberg L; Sage Bionetworks, Seattle, WA, USA., Wang Y; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., Jacobson C; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., Yapp C; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., Chung M; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., Vidovic D; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, 33136, USA.; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.; Institute for Data Science & Computing, University of Miami, Miami, FL, 33136, USA., Lu Y; Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schurer S; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, 33136, USA.; Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.; Institute for Data Science & Computing, University of Miami, Miami, FL, 33136, USA., Lee A; Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, USA., Pillai A; Human Genome Research Institute, National Institutes of Health, Bethesda, USA., Subramanian A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Papanastasiou M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fraenkel E; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Feiler HS; Department of Biomedical Engineering, OHSU, Portland, OR, USA.; Knight Cancer Institute, OHSU, Portland, OR, USA., Mills GB; Knight Cancer Institute, OHSU, Portland, OR, USA.; Division of Oncological Sciences, OHSU, Portland, OR, USA., Jaffe JD; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ma'ayan A; Department of Pharmacological Sciences, Mount Sinai Center for Bioinformatics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Birtwistle MR; Department of Chemical and Biomolecular Engineering, Clemson University, Clemson, SC, USA., Sorger PK; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA., Korkola JE; Department of Biomedical Engineering, OHSU, Portland, OR, USA.; Knight Cancer Institute, OHSU, Portland, OR, USA., Gray JW; Department of Biomedical Engineering, OHSU, Portland, OR, USA.; Knight Cancer Institute, OHSU, Portland, OR, USA., Heiser LM; Department of Biomedical Engineering, OHSU, Portland, OR, USA. heiserl@ohsu.edu.; Knight Cancer Institute, OHSU, Portland, OR, USA. heiserl@ohsu.edu.

Publikováno v: Communications biology [Commun Biol] 2022 Oct 07; Vol. 5 (1), pp. 1066. Date of Electronic Publication: 2022 Oct 07.

Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.

Autor: Jiang H; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Muir RK; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA., Gonciarz RL; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA., Olshen AB; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA., Yeh I; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Departments of Pathology and Dermatology, University of California, San Francisco, San Francisco, CA., Hann BC; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Zhao N; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA., Wang YH; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA., Behr SC; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA., Korkola JE; Center for Spatial Systems Biomedicine, Oregon Health & Sciences University, Portland, OR., Evans MJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA., Collisson EA; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Renslo AR; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA.

Publikováno v: The Journal of experimental medicine [J Exp Med] 2022 Apr 04; Vol. 219 (4). Date of Electronic Publication: 2022 Mar 09.